Long-term persistent lymphopenia in hematopoietic stem cell donors after donation for donor lymphocyte infusion

被引:7
|
作者
Nicolini, FE
Wattel, E
Michallet, AS
Bourgeot, JP
Tremisi, JP
Hequet, O
Michallet, M
机构
[1] Hop Edouard Herriot, Dept Hematol, Hematol Serv, F-69437 Lyon 03, France
[2] Hop Edouard Herriot, Etablissement Francais Sang, F-69437 Lyon, France
[3] Ctr Leon Berard, F-69373 Lyon, France
关键词
D O I
10.1016/j.exphem.2004.07.021
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To analyze the consequences of lymphocyte donations on lymphopoiesis in donors having previously undergone hematopoietic stem cell collection for allogeneic stem cell transplantation. Methods. Repeated analysis of leukocyte subsets in the peripheral blood of 76 hematopoietic stem cell donors undergoing lymphocyte donation(s) for DLI. Results. Grade I/II lymphopenia was present in 22 donors (29%) just before first apheresis for lymphocyte collection, demonstrating that former stem cell donation induced prolonged lymphopenia in a subset of donors. The monocytic lineage was not affected. Older age and history of PBSC harvest constituted 2 independent factors of lymphopenia, but had no influence on monocytopenia. The first apheresis induced lymphopenia in 36 donors (47%) and monocytopenia in 23 donors (39%). Lymphopenia before first apheresis and prior history of PBSC harvest were independent factors of apheresis-induced lymphopenia while those factors had no influence on monocytopenia. A time-dependent decrease in lymphocyte counts was observed in donors undergoing repeated aphereses, resulting in persistent and prolonged lymphopenia in 50% of donors. No persistent monocytopenia over time and aphereses was observed. Kaplan-Meier estimate of the risk to develop persistent lymphopenia after multiple aphereses was 21% +/- 6% at 2 months, 38% +/- 8% at 4 months, and 64% +/- 10% at 12 months. After Cox regression analysis, previous PBSC harvest remained the unique factor associated with the risk for persistent lymphopenia. Conclusions. Monitoring the potential long-term effects of repeated aphereses in hematopoietic stem cell donors appears important. Selecting young bone marrow donors for subsequent DLI significantly reduces the risk for acute and prolonged lymphopenias. (C) 2004 International Society for Experimental Hematology. Published by Elsevier Inc.
引用
收藏
页码:1033 / 1039
页数:7
相关论文
共 50 条
  • [1] Long-Term Survival After Donor Lymphocyte Infusion For Hematological Malignancies After Allogeneic Hematopoietic Cell Transplantation
    Worel, Nina
    Kalhs, Peter
    Rabitsch, Werner
    Mitterbauer, Margit
    Schulenburg, Axel
    Leitner, Gerda
    Greinix, Hildegard T.
    BLOOD, 2013, 122 (21)
  • [2] LONG-TERM SURVIVAL AFTER DONOR LYMPHOCYTE INFUSION FOR MOLECULAR AND HEMATOLOGICAL RELAPSE AFTER HEMATOPOIETIC CELL TRANSPLANTATION FOR MYELOFIBROSIS
    Gagelmann, Nico
    Wolschke, Christine
    Klyuchnikov, Evgeny
    Badbaran, Anita
    Berger, Susanna Carolina
    Ayuk, Francis
    Kroeger, Nicolaus
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 495 - 496
  • [3] Donor lymphocyte infusion for leukemia relapse after hematopoietic stem cell transplantation
    Yegin, Zeynep Arzu
    Ozkurt, Zuebeyde Nur
    Aki, Sahika Zeynep
    Sucak, Guelsan Tuerkoez
    TRANSFUSION AND APHERESIS SCIENCE, 2010, 42 (03) : 239 - 245
  • [4] Long-Term Remission After Nelarabine and Donor Lymphocyte Infusion in a Patient With T-ALL Who Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation
    Koruk, Kivanc
    Tiryaki, Tarik Onur
    Ozbalak, Murat
    Mastanzade, Metban
    Arslan, Oyku
    Besisik, Sevgi Kalayoglu
    Hindilerden, Ipek Yonal
    Nalcaci, Meliha
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S601 - S601
  • [5] DONOR-LYMPHOCYTE INFUSION IN PATIENTS WITH PERSISTENT OR RECURRENT MULTIPLE MYELOMA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
    Beitinjaneh, A.
    Shah, N.
    Bashir, Q.
    Parmar, S.
    Hosing, C.
    Popat, U.
    Anderlini, P.
    Dinh, Y.
    Qureshi, S.
    Rondon, G.
    Champlin, R. E.
    Giralt, S.
    Qazilbash, M. H.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (02) : S340 - S340
  • [6] Outcome of donor lymphocyte infusion for fall in chimerism after hematopoietic stem cell transplant
    Pandey, Prashant
    Setya, Divya
    Kaul, Esha
    Ranjan, Shweta
    Kumar, Praveen
    TRANSPLANT IMMUNOLOGY, 2020, 61
  • [7] Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation
    Helg, C
    Starobinski, M
    Jeannet, M
    Chapuis, B
    LEUKEMIA & LYMPHOMA, 1998, 29 (3-4) : 301 - 313
  • [8] Donor Lymphocyte Infusion for the Treatment and Prevention of Recurrence After Hematopoietic Stem Cell Transplantation
    Liao, Jianyun
    Long, Lina
    Li, Chunfu
    Zhou, Xiaohui
    Liu, Qifa
    BLOOD, 2012, 120 (21)
  • [9] Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia
    Christoph Schmid
    Myriam Labopin
    Nicolaas Schaap
    Hendrik Veelken
    Arne Brecht
    Michael Stadler
    Juergen Finke
    Frederic Baron
    Matthew Collin
    Gesine Bug
    Per Ljungman
    Didier Blaise
    Johanna Tischer
    Adrian Bloor
    Aleksander Kulagin
    Sebastian Giebel
    Norbert-Claude Gorin
    Jordi Esteve
    Fabio Ciceri
    Bipin Savani
    Arnon Nagler
    Mohamad Mohty
    Bone Marrow Transplantation, 2022, 57 : 215 - 223
  • [10] Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia
    Schmid, Christoph
    Labopin, Myriam
    Schaap, Nicolaas
    Veelken, Hendrik
    Brecht, Arne
    Stadler, Michael
    Finke, Juergen
    Baron, Frederic
    Collin, Matthew
    Bug, Gesine
    Ljungman, Per
    Blaise, Didier
    Tischer, Johanna
    Bloor, Adrian
    Kulagin, Aleksander
    Giebel, Sebastian
    Gorin, Norbert-Claude
    Esteve, Jordi
    Ciceri, Fabio
    Savani, Bipin
    Nagler, Arnon
    Mohty, Mohamad
    BONE MARROW TRANSPLANTATION, 2022, 57 (02) : 215 - 223